GSK | The Business Standard
Skip to main content
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
The Business Standard

Sunday
May 18, 2025

Sign In
Subscribe
  • Epaper
  • Economy
    • Aviation
    • Banking
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • Videos
    • TBS Today
    • TBS Stories
    • TBS World
    • News of the day
    • TBS Programs
    • Podcast
    • Editor's Pick
  • World+Biz
  • Features
    • Panorama
    • The Big Picture
    • Pursuit
    • Habitat
    • Thoughts
    • Splash
    • Mode
    • Tech
    • Explorer
    • Brands
    • In Focus
    • Book Review
    • Earth
    • Food
    • Luxury
    • Wheels
  • Subscribe
    • Epaper
    • GOVT. Ad
  • More
    • Sports
    • TBS Graduates
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • Gallery
    • Long Read
    • Interviews
    • Offbeat
    • Magazine
    • Climate Change
    • Health
    • Cartoons
  • বাংলা
SUNDAY, MAY 18, 2025

GSK

GSK licenses companies to make cheap copies of HIV prevention drug
World+Biz

GSK licenses companies to make cheap copies of HIV prevention drug

Unilever logo is displayed on Dove soap boxes in this illustration taken on January 17, 2022. REUTERS/Dado Ruvic/Illustration
World+Biz

Unilever CEO set to leave after GSK debacle, arrival of activist investor

The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020/ Reuters
Coronavirus chronicle

Healthcare companies Sanofi and GSK to seek Covid-19 vaccine regulatory approval

Unilever's offer for GSK's consumer health raises doubts, questions over strategy
Global Economy

Unilever's offer for GSK's consumer health raises doubts, questions over strategy

Unilever says it wants to buy GSK's consumer goods arm
Global Economy

Unilever says it wants to buy GSK's consumer goods arm

Photo: Collected
Coronavirus chronicle

New data shows GSK-Vir drug works against all Omicron mutations

Photo: Reuters
Coronavirus chronicle

UK approves GSK Covid drug, appears effective against Omicron

Photo: Collected
Coronavirus chronicle

GSK says tests show antibody drug works against Omicron

Photo: Collected
Health

GSK to develop longer-acting therapy for HIV with Japan's Shionogi

FILE PHOTO: The GlaxoSmithKline (GSK) logo on top of GSK Asia House is seen through vertical louvres in Singapore, March 21, 2018. Picture taken March 21, 2018. REUTERS/Loriene Perera
Coronavirus chronicle

Study confirms GSK-Vir antibody drug reduces hospitalisation, death in Covid-19 patients

FILE PHOTO: Former GlaxoSmithKline pharmaceutical executive Moncef Slaoui, who will serve as chief adviser on the effort to find a vaccine for the coronavirus disease (Covid-19) pandemic, listens while wearing a protective face mask as President Donald Trump holds a coronavirus disease vaccine event in the Rose Garden at the White House in Washington, US, May 15, 2020. REUTERS/Kevin Lamarque
World+Biz

GSK fires former US govt vaccine head Slaoui over harassment allegation

Photo: Collected
Coronavirus chronicle

GSK, Sanofi begin new Covid-19 vaccine trial of protein-based vaccine

Photo: Collected
Coronavirus chronicle

GSK, Vir Biotech to expand Covid -19 research partnership for other diseases

  • Show More
  • loading...
EMAIL US
contact@tbsnews.net
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Advertisement
  • Privacy Policy
  • Comment Policy
Copyright © 2025
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - oped.tbs@gmail.com

For advertisement- sales@tbsnews.net